Oncology News | pharmaphorum

News

BMS grabs key approval for Reblozyl in MDS

Bristol-Myers Squibb's blockbuster aspirations for Reblozyl have been given a boost by the FDA after it approved the drug as a first-line treatment for anaemia in patients

News

BMS backs $255m round for contract cell maker Cellares

Cellares has just closed a major $255 million third-round financing that will be used to complete a highly automated facility in New Jersey for the production of cell ther

News

'Inadvertent' leak teases survival benefit for Roche's TIGIT

In an unusual development, Roche has put out a statement this morning acknowledging an "inadvertent disclosure" of data from its SKYSCRAPER-01 study of anti-TIGIT drug tir

News

FDA places Gilead's CD47 drug on another clinical hold

Gilead is dealing with more turbulence in its development of CD47-targeting antibody magrolimab, with a partial clinical hold placed on the drug by the FDA in acute myeloi

News

UK study prompts call for MRI screening for prostate cancer

A UK study has suggested that a 10-minute MRI scan is more effective at detecting prostate cancer than testing for blood levels of the biomarker PSA, picking up serious ca

News

Trial backs use of Cabometyx, Tecentriq in prostate cancer

Ipsen and Exelixis could expand the use of blockbuster oncology drug Cabometyx into prostate cancer, based on data from a phase 3 study – and help bring a cancer immunothe

BMS grabs key approval for Reblozyl in MDS

BMS backs $255m round for contract cell maker Cellares

'Inadvertent' leak teases survival benefit for Roche's TIGIT

FDA places Gilead's CD47 drug on another clinical hold

UK study prompts call for MRI screening for prostate cancer

Trial backs use of Cabometyx, Tecentriq in prostate cancer

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks